CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

All Clinical Trials for Heparin Sodium 25,000 Units In Dextrose 5%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000468 ↗	Myocardial Infarction Triage and Intervention Project (MITI)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1988-04-01	To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 ↗	Myocardial Infarction Triage and Intervention Project (MITI)	Completed	University of Washington	Phase 3	1988-04-01	To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Australian and New Zealand Intensive Care Society Clinical Trials Group	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Canadian Critical Care Trials Group	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Canadian Institutes of Health Research (CIHR)	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	McMaster University	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.

Clinical Trial Conditions for Heparin Sodium 25,000 Units In Dextrose 5%

Condition Name

Condition Name for Heparin Sodium 25,000 Units In Dextrose 5%
Intervention	Trials
Healthy	4
Thrombosis	4
Covid19	4
Myocardial Infarction	4

Condition MeSH

Condition MeSH for Heparin Sodium 25,000 Units In Dextrose 5%
Intervention	Trials
Thrombosis	13
Venous Thrombosis	7
Acute Kidney Injury	6
COVID-19	6

Clinical Trial Locations for Heparin Sodium 25,000 Units In Dextrose 5%

Trials by Country

Trials by Country for Heparin Sodium 25,000 Units In Dextrose 5%
Location	Trials
United States	44
China	16
Canada	14
Brazil	12
Germany	11

Trials by US State

Trials by US State for Heparin Sodium 25,000 Units In Dextrose 5%
Location	Trials
California	7
New York	5
Texas	4
Ohio	3
Maryland	2

Clinical Trial Progress for Heparin Sodium 25,000 Units In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 25,000 Units In Dextrose 5%
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	15
Phase 2/Phase 3	6

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 25,000 Units In Dextrose 5%
Clinical Trial Phase	Trials
Completed	47
Unknown status	13
Withdrawn	10

Clinical Trial Sponsors for Heparin Sodium 25,000 Units In Dextrose 5%

Sponsor Name

Sponsor Name for Heparin Sodium 25,000 Units In Dextrose 5%
Sponsor	Trials
Ain Shams University	5
Azidus Brasil	4
GlaxoSmithKline	4

Sponsor Type

Sponsor Type for Heparin Sodium 25,000 Units In Dextrose 5%
Sponsor	Trials
Other	143
Industry	35
NIH	5

Heparin Sodium 25,000 Units in Dextrose 5%: Clinical Trials, Market Analysis, and Future Market Projections

Last updated: October 28, 2025

---

Introduction

Heparin Sodium, particularly in the 25,000 Units in Dextrose 5% formulation, remains a cornerstone anticoagulant in clinical settings worldwide. It is primarily utilized to prevent and treat thromboembolic events in hospitalized patients undergoing surgery, dialysis, or suffering from coagulopathies. As the pharmaceutical landscape evolves with ongoing clinical research and shifting market dynamics, understanding recent developments and future projections becomes essential for stakeholders. This report offers a comprehensive update on clinical trials, an analysis of the current market landscape, and future market forecasts of Heparin Sodium 25,000 Units in Dextrose 5%.

---

Clinical Trials Landscape

Ongoing and Recent Clinical Trials

The clinical development of heparin formulations focuses on safety, efficacy, and optimizing dosing parameters. In recent years, several phase IV and observational studies have explored the broader application of Heparin Sodium 25,000 Units in Dextrose 5%. Major ongoing trials include:

• Safety and Efficacy in ECMO Patients: Multiple studies examine the anticoagulant’s role in extracorporeal membrane oxygenation (ECMO), assessing bleeding risk versus thrombosis prevention [1].

• Use in COVID-19-Related Coagulopathy: Given the pro-thrombotic complications of COVID-19, trials have explored heparin-based therapies, including Heparin Sodium 25,000 Units, to prevent thrombosis without excessive bleeding [2].

• Optimizing Dosing Strategies: Recent research investigates dosing adjustments based on patient weight, renal function, and laboratory parameters to enhance safety and efficacy.

Regulatory and Post-Marketing Surveillance

Regulatory agencies like the FDA and EMA continue to require post-marketing surveillance to monitor adverse events, especially bleeding risks associated with high-dose heparin. These data influence labeling updates and clinical guidelines, shaping the product’s future application landscape.

Innovative Delivery and Formulation Trials

Attempts to improve administration and patient compliance include exploring alternative dosing methods and formulations, such as subcutaneous injections and reduced infusion durations, to enhance operational efficiency in hospitals.

---

Market Analysis

Current Market Landscape

The global heparin market was valued at approximately USD 2.5 billion in 2022 and is projected to grow at a CAGR of around 6% through 2030 [3]. Heparin Sodium 25,000 Units in Dextrose 5% dominates the hospital anticoagulation segment due to its established efficacy and familiarity among clinicians.

Key market players include Pfizer, Fresenius Kabi, and B. Braun Melsungen, which manufacture diverse heparin formulations. Pfizer’s approval of Heparin Sodium injection remains a market leader owing to its extensive distribution network and market penetration.

Regional Distribution and Dynamics

• North America: The largest market, driven by high healthcare expenditure, prevalence of thromboembolic disorders, and well-established clinical protocols.

• Europe: Significant adoption attributed to stringent regulatory oversight and demand for reliable anticoagulants.

• Asia-Pacific: Rapidly growing due to expanding healthcare infrastructure, increasing surgeries, and rising awareness.

Market Challenges

Despite its widespread use, the market faces challenges:

• Safety Concerns: Elevated bleeding risk and heparin-induced thrombocytopenia (HIT) have prompted clinicians to seek alternative anticoagulants, influencing market growth.

• Regulatory Scrutiny: Enhanced post-marketing surveillance and tighter regulations may impact manufacturing and distribution.

• Availability of Alternatives: The rising use of low-molecular-weight heparins (LMWH) and direct oral anticoagulants (DOACs) provides competition.

---

Market Projections

Growth Drivers

• Expanding Surgical Procedures and ICU Cases: Rising global surgical volumes and critical care admissions sustain demand.

• COVID-19 and Thromboprophylaxis: The pandemic underscored the critical need for effective anticoagulation, reinforcing the importance of heparin.

• Regulatory Approvals and Label Expansions: Continued approvals for new indications could expand market size.

Forecast for 2025-2030

The Heparin Sodium 25,000 Units in Dextrose 5% segment is projected to maintain a steady CAGR of around 5-6%. The market is anticipated to reach approximately USD 4.2 billion by 2030, driven by increased hospitalizations, surgical procedures, and ongoing clinical validations supporting its use.

Emerging Trends

• Preference for Heparin Alternatives: Continuous monitoring of clinical trial outcomes may slow or accelerate growth, depending on safety profiles.

• Innovation in Formulation: Development of safer, more targeted delivery systems could unlock new market segments.

• Regulation-Informed Supply Chain Adjustments: Companies adapting swiftly to regulatory changes will secure market share.

---

Key Considerations for Stakeholders

• Pharmaceutical Manufacturers: Need ongoing clinical trials and safety data to sustain market leadership and meet regulatory standards.

• Investors: Opportunities exist in companies investing in formulation improvements and compliance innovations.

• Healthcare Providers: Emphasize the importance of adhering to evolving protocols that balance efficacy and safety.

• Policy Makers: Ensure regulatory frameworks promote safe, evidence-based use of heparin products.

---

Key Takeaways

• The clinical trial landscape for Heparin Sodium 25,000 Units in Dextrose 5% is active, focusing on safety, efficacy, and alternative administration routes, especially amid evolving COVID-19 treatment protocols.

• The global heparin market remains robust, buoyed by demographic trends, procedural volume increases, and pandemic-related thrombotic concerns, with a forecasted valuation of USD 4.2 billion by 2030.

• Safety concerns associated with bleeding and HIT continue to influence formulations, prescribing practices, and regulatory scrutiny, shaping future product development.

• Market growth is expected to remain steady, with innovations in delivery systems and ongoing clinical evaluations serving as potential catalysts.

• Stakeholders should monitor regulatory developments and clinical trial outcomes closely, adapting strategies accordingly.

---

FAQs

1. What are the main clinical applications of Heparin Sodium 25,000 Units in Dextrose 5%?
It is primarily used for anticoagulation in surgical procedures, dialysis, intensive care settings, and to treat or prevent deep vein thrombosis and pulmonary embolism.

2. How do recent clinical trials impact the use of heparin formulations?
They provide evidence on safety and dosing adjustments, influence clinical guidelines, and can lead to expanded indications or restrictive protocols based on risk profiles.

3. What are the emerging safety concerns associated with high-dose heparin?
Major concerns include bleeding risks and heparin-induced thrombocytopenia (HIT), prompting ongoing surveillance and protocol refinements.

4. How is the market for Heparin Sodium expected to evolve in the coming decade?
It is projected to grow moderately, driven by procedural volume increases, pandemic-related demand, and technological innovations, despite competition from newer anticoagulants.

5. Are there innovative alternatives to traditional heparin formulations?
Yes, low-molecular-weight heparins and direct oral anticoagulants offer alternative options, though they have different safety profiles and indications.

---

Sources

[1] ClinicalTrials.gov. "Evaluation of Heparin in ECMO," 2022.
[2] World Health Organization. "Management of COVID-19 Coagulopathy," 2021.
[3] MarketsandMarkets. "Global Heparin Market Forecast," 2022.